- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05250752
Reduction of Peritoneal Glucose Uptake With Use of SGLT2 in Humans Undergoing Peritoneal Dialysis Treatment (PRESERVE)
Reduction of Peritoneal Glucose Uptake With Use of SGLT2 in Humans Undergoing Peritoneal Dialysis Treatment. A Proof of Concept Phase 2a Clinical Trial.
End stage renal disease is annually diagnosed in about one thousand patients in Denmark, and one of the treatment modalities in renal replacement therapy is peritoneal dialysis with about 25 % of patients assigned to this treatment (Hommel2010). Peritoneal dialysis is based on the principle of filtering waste products to peritoneal fluid and by exchange of peritoneal fluid eliminate waste products from the body.
In peritoneal dialysis commonly used fluids contain glucose. Exposure to high glucose levels in peritoneal fluid during peritoneal dialysis has several side effects. Primarily, as glucose passes over and into the peritoneal membrane it causes local inflammation which leads to fibrosis over time (Zhou2016). Fibrosis limits the capacity of the exchange of water and waste products over the peritoneal membrane. The decrease of peritoneal exchange capacity is most commonly the reason for termination of peritoneal dialysis.
SGLT2-channels are identified in peritoneal mesothelial cells of rats (Debray-Carcia 2016), and most recently also in humans (Shentu2021). An in vitro model of human peritoneal mesothelial cells incubated with the SGLT2-inhibitor (empagliflozin) has shown significantly decrease in glucose uptake (Zhou2019). Exposure to intraperitoneal empagliflozin in rats, reduced the uptake of glucose over the peritoneal membrane significantly by 78 % and the ultrafiltration was increased (Zhou2019).
Currently, to our knowledge, no clinical trials have been conducted in humans attending peritoneal dialysis with the aim of investigating either the effect or safety of SGLT2i, as it is indeed the first of its kind, with the aim of including participants in peritoneal dialysis.
Study Overview
Status
Intervention / Treatment
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Zealand
-
Holbæk, Zealand, Denmark, 4300
- University Hospital Copenhagen - Holbaek
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Written informed consent
- Age above 18 years of age
- In stable peritoneal dialysis for more than 14 days.
Exclusion Criteria:
- In treatment with SGLT2i currently or within the last 90 days.
- Treatment for peritoneal infection within the last 30 days.
- Any hospitalization within the last 30 days.
- Anaphylaxis to the IMP.
- Impaired lever function with ALAT above normal range within the last 6 month.
- Sever efflux problems during peritoneal dialysis for the last 14 days, judged by the investigator.
- Non-menopausal defined as menstruation within the last 12 month without any other medical cause. Only applicable for female participants.
- Substance abuse, judged by the investigator.
- Incapable to follow study protocol, judged by the investigator.
- Previously included in this clinical trial and exposed to the IMP.
- Included in another clinical trial with exposure to any IMP within the last 30 days.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: On treatment
Assigned to oral treatment with dapagliflozin 10 mg for three consecutive days.
|
Primary end-points are measure before (day 0), on treatment (day 1 and day 3) and after treatment (day 21)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Peritoneal glucose uptake (mg/ dL)
Time Frame: Day 0 (baseline), Day 3 (max dose of treatment)
|
Glucose level in peritoneal fluid during a four hour standardized peritoneal dialysis.
Change in total glucose uptake before and after treatment (treatment periode of three days)
|
Day 0 (baseline), Day 3 (max dose of treatment)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Fluid volume (ml)
Time Frame: Measured at end of each peritoneal dialysis. Peritoneal dialysis done af Day 0, Day 1 (first day of treatment) and day 3 (max dose of treatment)
|
Fluid volume ultra-filtrated during peritoneal dialysis.
|
Measured at end of each peritoneal dialysis. Peritoneal dialysis done af Day 0, Day 1 (first day of treatment) and day 3 (max dose of treatment)
|
Plasma glucose level (mg/ dL)
Time Frame: Measured at end of each peritoneal dialysis. Peritoneal dialysis done af Day 0, Day 1 (first day of treatment) and day 3 (max dose of treatment).
|
Glucose levels in blood and peritoneal-fluid during peritoneal dialysis.
Comparaison of maximal plasma level.
|
Measured at end of each peritoneal dialysis. Peritoneal dialysis done af Day 0, Day 1 (first day of treatment) and day 3 (max dose of treatment).
|
Pharmacokinetics (nmol)
Time Frame: Samples for biobank - samples drawn at end of each peritoneal dialysis. Peritoneal dialysis done af Day 0, Day 1 (first day of treatment) and day 3 (max dose of treatment). Samples are drawn every 30 minuttes during each peritoneal dialysis.
|
Dapagliflozin and its metabolites levels in blood and peritoneal-fluid
|
Samples for biobank - samples drawn at end of each peritoneal dialysis. Peritoneal dialysis done af Day 0, Day 1 (first day of treatment) and day 3 (max dose of treatment). Samples are drawn every 30 minuttes during each peritoneal dialysis.
|
Adverse events (events)
Time Frame: At day 1 (first day of treatment), day 3 (max dose of treatment) and day 30 (four weeks after treatment)
|
Safety in terms of AE and/or SAE
|
At day 1 (first day of treatment), day 3 (max dose of treatment) and day 30 (four weeks after treatment)
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Morten Lindhardt, MD, PhD, Copenhagen University Hospital - Holbaek
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- HOL-MED-01-2021
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- Study Protocol
- Statistical Analysis Plan (SAP)
- Informed Consent Form (ICF)
- Clinical Study Report (CSR)
- Analytic Code
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on End Stage Renal Disease
-
Outset MedicalCompletedAcute Kidney Injury | End Stage Renal Disease (ESRD) | End Stage Renal Disease on DialysisUnited States
-
University of Illinois at ChicagoWithdrawnObesity | End-Stage Renal Disease | Renal Disease, End-Stage | Renal Failure, End-StageUnited States
-
Bioconnect Systems, IncCompletedEnd-stage Renal Disease | End-stage Kidney DiseaseUnited States
-
Xinhua Hospital, Shanghai Jiao Tong University...Changhai Hospital; Shanghai Zhongshan Hospital; RenJi Hospital; Ruijin Hospital; Shanghai... and other collaboratorsCompleted
-
Clinical Research Center for End Stage Renal Disease...Kyungpook National University Hospital; Medical Research Collaborating Center... and other collaboratorsActive, not recruitingEnd-Stage Renal DiseaseKorea, Republic of
-
Medtronic - MITGCompletedEnd-stage Renal DiseaseGermany
-
China Medical University HospitalUnknown
-
Guangdong Provincial Hospital of Traditional Chinese...Ministry of Science and Technology of the People´s Republic of ChinaUnknown
-
University of California, San FranciscoCompletedEnd-stage Renal DiseaseUnited States
-
Mark A. LumleyHenry Ford Health SystemCompleted
Clinical Trials on Dapagliflozin 10 MG [Farxiga]
-
Jiangsu Hansoh Pharmaceutical Co., Ltd.Completed
-
Jiangsu Hansoh Pharmaceutical Co., Ltd.Completed
-
Fundación Pública Andaluza para la Investigación...Unknown
-
George Clinical Pty LtdUniversity Medical Center Groningen; Ground Zero PharmaceuticalsUnknownDiabetes Mellitus, Type 2 | Impaired Renal FunctionCanada
-
Sheba Medical CenterUnknownCoronary Disease With Diabetes MellitusIsrael
-
University of Campinas, BrazilAstraZenecaCompletedCoronary Artery Disease | Diabetes Mellitus, Type 2 | Carotid Artery DiseasesBrazil
-
Dong-A UniversityRecruitingRenal Insufficiency, Chronic | Percutaneous Coronary Intervention | Cardiac CatheterizationKorea, Republic of
-
Northwestern UniversityNational Heart, Lung, and Blood Institute (NHLBI); National Institutes of Health...RecruitingHeart Failure | Kidney Diseases | Chronic Kidney Diseases | Heart Failure With Preserved Ejection FractionUnited States
-
Chang Gung Memorial HospitalActive, not recruitingCatheter Ablation | Atrial Fibrillation RecurrentTaiwan
-
Hospital General Universitario Gregorio MarañonInstituto de Salud Carlos III; University of Navarra; Fundación para la Investigación...UnknownDiabetes Mellitus, Type 2 | Heart Failure With Preserved Ejection FractionSpain